Combining therapies to treat a specific type of bladder cancer with genetic vulnerabilities
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
This study is looking for better treatment options for people with metastatic bladder cancer who have a specific genetic change, hoping to find out why some don’t respond well to current immunotherapies and to create new strategies that work better for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10881800 on NIH RePORTER |
What this research studies
This research focuses on developing effective combination therapies for patients with metastatic bladder cancer that have a specific genetic alteration known as homozygous deletion of the MTAP gene. The study aims to understand why some patients do not respond well to existing immunotherapies and to identify new treatment strategies that can enhance their effectiveness. By targeting the unique metabolic and immune characteristics of this cancer subtype, the research seeks to improve patient outcomes through tailored therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic bladder cancer who have the homozygous deletion of the MTAP gene.
Not a fit: Patients with bladder cancer who do not have the MTAP gene deletion or those with non-metastatic bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with a specific type of metastatic bladder cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting specific genetic vulnerabilities in cancers, suggesting that this approach could lead to meaningful advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Gao, Jianjun — University of Tx Md Anderson Can Ctr
- Study coordinator: Gao, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.